10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 10x Genomics, Inc. on May 7, 2026. The filing serves to announce the Company's financial results for the quarter ended March 31, 2026, pursuant to Item 2.02.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The 8-K acts as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1, but the text of the press release is not included in the source data.
Material Changes
The filing text does not provide data to compare current period performance against prior comparable periods. No specific material changes in financial condition or operations are detailed within the 8-K body text.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. These disclosures are contained within the attached press release (Exhibit 99.1), which is not part of the provided input text.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q1 2026 revenue and net income figures.
- Verify year-over-year growth rates and gross margin trends in the full press release.
- Check for updated full-year 2026 financial guidance provided by management.
- Confirm cash position and liquidity metrics as reported in the detailed results.